Neuroimaging in Clinical Assessment

On this page

Neuroimaging in Clinical Assessment - Brain Blueprints

Structural neuroimaging visualizes brain anatomy; key for ruling out organic causes.

  • Computed Tomography (CT)
    • Principle: X-ray based; measures tissue density.
    • Indications: Acute head trauma, suspected intracranial bleed, stroke.
    • Pros: Fast, accessible.
    • Cons: Radiation, less soft tissue detail than MRI.
  • Magnetic Resonance Imaging (MRI)
    • Principle: Magnetic fields & radio waves.
    • Indications: Detailed soft tissue, white/gray matter lesions.
    • Pros: Superior detail, no radiation.
    • Cons: Slower, costlier, metal contraindications.
    • Key Sequences:
      • T1-weighted: Anatomy (CSF dark). 📌 T1: Anatomy.
      • T2-weighted: Pathology (CSF bright). 📌 T2: H2O bright.
      • FLAIR: T2-like, CSF dark; highlights periventricular lesions (e.g., MS).

⭐ MRI is superior to CT for detecting subtle structural brain abnormalities, white matter lesions (e.g., multiple sclerosis), and early ischemic changes.

CT vs MRI Brain Scansoka

Neuroimaging in Clinical Assessment - Mind at Work

Functional neuroimaging provides dynamic insights into brain activity, blood flow, and neurochemistry.

  • Functional MRI (fMRI):
    • Measures brain activity by detecting changes in blood oxygenation (BOLD signal).
    • Non-invasive, no radiation. High spatial, moderate temporal resolution.
    • Uses: Cognitive research, mapping eloquent cortex pre-surgery.
  • Positron Emission Tomography (PET):
    • Visualizes metabolic processes (e.g., FDG for glucose metabolism) or receptor binding using radiolabeled tracers.
    • Involves ionizing radiation.
    • Uses: Alzheimer's (hypometabolism), Parkinson's (dopamine), oncology.

    ⭐ PET with 18F-FDG often reveals characteristic bilateral temporoparietal hypometabolism in Alzheimer's disease.

  • Single Photon Emission CT (SPECT):
    • Measures regional cerebral blood flow (rCBF) or neurotransmitter receptor availability.
    • Uses gamma-emitting radiotracers; less resolution and sensitivity than PET.
    • Uses: Dementia (perfusion), epilepsy (ictal vs. interictal), cerebrovascular disease.
  • Magnetic Resonance Spectroscopy (MRS):
    • Detects and quantifies brain metabolites (e.g., N-acetylaspartate (NAA), choline, creatine, lactate).
    • Non-invasive; provides biochemical information.
    • Uses: Differentiating tumor types, metabolic encephalopathies, research in mood disorders. Brain MRI scans on tablet

Neuroimaging in Clinical Assessment - Disorder Snapshots

  • Schizophrenia: ↑ Ventricular size (lateral, third); ↓ cortical volume (frontal, temporal); hypofrontality (DLPFC).
  • Major Depressive Disorder (MDD): ↓ Hippocampal volume; ↑ amygdala activity (negative stimuli); ↓ DLPFC activity (cognitive tasks).
  • Bipolar Disorder: ↑ White matter hyperintensities; ↓ prefrontal cortex volume; altered amygdala-prefrontal connectivity.
  • Obsessive-Compulsive Disorder (OCD): Orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), striatal (caudate) abnormalities; functional: ↑ Cortico-Striato-Thalamo-Cortical (CSTC) loop hyperactivity.
  • Post-Traumatic Stress Disorder (PTSD): ↓ Hippocampal & ACC volume; ↑ amygdala reactivity (trauma cues); ↓ medial prefrontal cortex (mPFC) activation.
  • Alzheimer's Disease: Medial temporal lobe atrophy (hippocampus, entorhinal cortex); ↓ temporoparietal glucose metabolism (FDG-PET).
  • ADHD: ↓ Volume: prefrontal cortex, basal ganglia, cerebellum; hypoactivation in frontostriatal networks.

⭐ Ventricular enlargement (lateral ventricles) is a consistent structural MRI finding in schizophrenia.

Neuroimaging in Clinical Assessment - Lens Limitations

  • Supportive, Not Definitive: Rules out organic causes; not diagnostic for most psychiatric disorders.
  • Low Specificity/Sensitivity: For primary psychiatric conditions, limiting individual diagnostic use.
  • Incidental Findings: Can create anxiety, necessitate further costly investigations.
  • Cost & Access: Significant barriers to routine clinical application.
  • Research-Clinical Gap: Group findings often not applicable to individual patients.

    ⭐ Key role: Exclude organic mimics (e.g., tumor, stroke) in atypical psychiatric symptoms via CT/MRI.

  • Interpretation Variability: Subjectivity can impact reliability.

High‑Yield Points - ⚡ Biggest Takeaways

  • Structural neuroimaging (CT, MRI) primarily rules out organic causes of psychiatric symptoms.
  • MRI offers superior soft-tissue contrast over CT for detecting subtle brain changes.
  • Functional neuroimaging (fMRI, PET, SPECT) remains largely a research tool, not for routine psychiatric diagnosis.
  • SPECT/PET can visualize cerebral blood flow, metabolism, or neuroreceptor occupancy.
  • No pathognomonic neuroimaging findings exist for most primary psychiatric illnesses like schizophrenia or bipolar disorder.
  • Hippocampal atrophy on MRI may be associated with chronic depression or Alzheimer's disease.
  • Ventricular enlargement and cortical atrophy are non-specific findings sometimes observed in schizophrenia cases.

Practice Questions: Neuroimaging in Clinical Assessment

Test your understanding with these related questions

Which radiopharmaceutical is commonly used in positron emission tomography (PET) imaging?

1 of 5

Flashcards: Neuroimaging in Clinical Assessment

1/10

Mini-Mental State Examination (MMSE, also known as _____ test) is a score out of 30 and is used to measure cognitive impairment.

TAP TO REVEAL ANSWER

Mini-Mental State Examination (MMSE, also known as _____ test) is a score out of 30 and is used to measure cognitive impairment.

Folstein's

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial